Cantex Pharmaceuticals, Inc.: CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

(marketscreener.com) Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diagnosed glioblastoma WESTON, Fla., March 19, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on...https://www.marketscreener.com/quote/stock/VTV-THERAPEUTICS-INC-23175037/news/CANTEX-PHARMACEUTICALS-TO-PRESENT-AT-5TH-ANNUAL-GLIOBLASTOMA-DRUG-DEVELOPMENT-SUMMIT-46231219/?utm_medium=RSS&utm_content=20240319